IL-18 enhances immunosuppressive responses by promoting differentiation into monocytic myeloid-derived suppressor cells

Journal of Immunology

Volumn 193, Issue 11, 2014, Pages 5453-5460

  Lim, Hui Xuan ^a   Hong, Hye Jin ^a   Cho, Daeho ^b   Kim, Tae Sung ^a  

^a Korea University   (South Korea)

^b Sookmyung Women's University   (South Korea)

Author keywords

[No Author keywords available]

Indexed keywords

ARGINASE 1; CD11B ANTIGEN; ENDOTOXIN; GAMMA INTERFERON; INTERLEUKIN 18; NITRIC OXIDE; REACTIVE OXYGEN METABOLITE; ARGINASE; ARGINASE I, HUMAN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BONE MARROW PROGENITOR CELL; CELL DIFFERENTIATION; CONCENTRATION RESPONSE; CONTROLLED STUDY; FEMALE; GRANULOCYTIC MYELOID DERIVED SUPPRESSOR CELL; IN VIVO STUDY; INTERFERON PRODUCTION; LYMPHOCYTE PROLIFERATION; MELANOMA B16; MONOCYTIC MYELOID DERIVED SUPPRESSOR CELL; MOUSE; NONHUMAN; SUPPRESSOR CELL; T LYMPHOCYTE; TUMOR MICROENVIRONMENT; ANIMAL; BONE MARROW CELL; C57BL MOUSE; CELL CULTURE; CELL PROLIFERATION; HUMAN; IMMUNOLOGY; IMMUNOSUPPRESSIVE TREATMENT; LYMPHOCYTE ACTIVATION; METABOLISM; MONOCYTE;

ANIMALS; ANTIGENS, CD11B; ARGINASE; CELL DIFFERENTIATION; CELL PROLIFERATION; CELLS, CULTURED; FEMALE; HUMANS; IMMUNOSUPPRESSION; INTERFERON-GAMMA; INTERLEUKIN-18; LYMPHOCYTE ACTIVATION; MICE; MICE, INBRED C57BL; MONOCYTES; MYELOID CELLS; NITRIC OXIDE; T-LYMPHOCYTES;

EID: 84912553327     PISSN: 00221767     EISSN: 15506606     Source Type: Journal    
DOI: 10.4049/jimmunol.1401282     Document Type: Article

References (43)

1. Gabrilovich, D. I., and S. Nagaraj. 2009. Myeloid-derived suppressor cells as regulators of the immune system. Nat. Rev. Immunol. 9: 162-174.
2. Talmadge, J. E., and D. I. Gabrilovich. 2013. History of myeloid-derived suppressor cells. Nat. Rev. Cancer 13: 739-752.
3. Youn, J.-I., S. Nagaraj, M. Collazo, and D. I. Gabrilovich. 2008. Subsets of myeloidderived suppressor cells in tumor-bearing mice. J. Immunol. 181: 5791-5802.
4. Tian, J., J. Ma, K. Ma, H. Guo, S. E. Baidoo, Y. Zhang, J. Yan, L. Lu, H. Xu, and S. Wang. 2013. β-Glucan enhances antitumor immune responses by regulating differentiation and function of monocytic myeloid-derived suppressor cells. Eur. J. Immunol. 43: 1220-1230.
5. Lebel-Binay, S., A. Berger, F. Zinzindohoué, P. Cugnenc, N. Thiounn, W. H. Fridman, and F. Pagès. 2000. Interleukin-18: biological properties and clinical implications. Eur. Cytokine Netw. 11: 15-26.
6. Stoll, S., H. Jonuleit, E. Schmitt, G. Müller, H. Yamauchi, M. Kurimoto, J. Knop, and A. H. Enk. 1998. Production of functional IL-18 by different subtypes of murine and human dendritic cells (DC): DC-derived IL-18 enhances IL-12-dependent Th1 development. Eur. J. Immunol. 28: 3231-3239.
7. Dinarello, C. A., and G. Fantuzzi. 2003. Interleukin-18 and host defense against infection. J. Infect. Dis. 187(Suppl 2): S370-S384.
8. Kinjo, Y., K. Kawakami, K. Uezu, S. Yara, K. Miyagi, Y. Koguchi, T. Hoshino, M. Okamoto, Y. Kawase, K. Yokota, et al. 2002. Contribution of IL-18 to Th1 response and host defense against infection by Mycobacterium tuberculosis: a comparative study with IL-12p40. J. Immunol. 169: 323-329.
9. Denton, A. E., P. C. Doherty, S. J. Turner, and N. L. La Gruta. 2007. IL-18, but not IL-12, is required for optimal cytokine production by influenza virus-specific CD8 + T cells. Eur. J. Immunol. 37: 368-375.
10. Park, S., S. Cheon, and D. Cho. 2007. The dual effects of interleukin-18 in tumor progression. Cell. Mol. Immunol. 4: 329-335.
11. Kim, K. E., H. Song, T. S. Kim, D. Yoon, C. W. Kim, S. I. Bang, D. Y. Hur, H. Park, and D. H. Cho. 2007. Interleukin-18 is a critical factor for vascular endothelial growth factor-enhanced migration in human gastric cancer cell lines. Oncogene 26: 1468-1476.
12. Jung, M. K., H. K. Song, K. E. Kim, D. Y. Hur, T. Kim, S. Bang, H. Park, and D. H. Cho. 2006. IL-18 enhances the migration ability of murine melanoma cells through the generation of ROI and the MAPK pathway. Immunol. Lett. 107: 125-130.
13. Cho, D., H. Song, Y. M. Kim, D. Houh, D. Y. Hur, H. Park, D. Yoon, K. H. Pyun, W. J. Lee, M. Kurimoto, et al. 2000. Endogenous interleukin-18 modulates immune escape of murine melanoma cells by regulating the expression of Fas ligand and reactive oxygen intermediates. Cancer Res. 60: 2703-2709.
14. Steding, C. E., S. T. Wu, Y. Zhang, M. H. Jeng, B. D. Elzey, and C. Kao. 2011. The role of interleukin-12 on modulating myeloid-derived suppressor cells, increasing overall survival and reducing metastasis. Immunology 133: 221-238.
15. Ribechini, E., V. Greifenberg, S. Sandwick, and M. B. Lutz. 2010. Subsets, expansion and activation of myeloid-derived suppressor cells. Med. Microbiol. Immunol. (Berl.) 199: 273-281.
16. Elkabets, M., V. S. Ribeiro, C. A. Dinarello, S. Ostrand-Rosenberg, J. P. Di Santo, R. N. Apte, and C. A. Vosshenrich. 2010. IL-1b regulates a novel myeloid-derived suppressor cell subset that impairs NK cell development and function. Eur. J. Immunol. 40: 3347-3357.
17. Ogura, T., H. Ueda, K. Hosohara, R. Tsuji, Y. Nagata, S. Kashiwamura, and H. Okamura. 2001. Interleukin-18 stimulates hematopoietic cytokine and growth factor formation and augments circulating granulocytes in mice. Blood 98: 2101-2107.
18. De Santo, C., M. Salio, S. H. Masri, L. Y. Lee, T. Dong, A. O. Speak, S. Porubsky, S. Booth, N. Veerapen, G. S. Besra, et al. 2008. Invariant NKT cells reduce the immunosuppressive activity of influenza A virus-induced myeloidderived suppressor cells in mice and humans. J. Clin. Invest. 118: 4036-4048.
19. Chatterjee, S., S. Das, P. Chakraborty, A. Manna, M. Chatterjee, and S. K. Choudhuri. 2013. Myeloid derived suppressor cells (MDSCs) can induce the generation of Th17 response from naive CD4+ T cells. Immunobiology 218: 718-724.
20. Yi, H., C. Guo, X. Yu, D. Zuo, and X. Y. Wang. 2012. Mouse CD11b+Gr-1+ myeloid cells can promote Th17 cell differentiation and experimental autoimmune encephalomyelitis. J. Immunol. 189: 4295-4304.
21. Corzo, C. A., T. Condamine, L. Lu, M. J. Cotter, J. I. Youn, P. Cheng, H. I. Cho, E. Celis, D. G. Quiceno, T. Padhya, et al. 2010. HIF-1α regulates function and differentiation of myeloid-derived suppressor cells in the tumor microenvironment. J. Exp. Med. 207: 2439-2453.
22. Lim, H. X., H. J. Hong, M. Y. Jung, D. Cho, and T. S. Kim. 2013. Principal role of IL-12p40 in the decreased Th1 and Th17 responses driven by dendritic cells of mice lacking IL-12 and IL-18. Cytokine 63: 179-186.
23. Morales, J. K., M. Kmieciak, K. L. Knutson, H. D. Bear, and M. H. Manjili. 2010. GM-CSF is one of the main breast tumor-derived soluble factors involved in the differentiation of CD11b¯Gr1¯ bone marrow progenitor cells into myeloid-derived suppressor cells. Breast Cancer Res. Treat. 123: 39-49.
24. Yan, D., Q. Yang, M. Shi, L. Zhong, C. Wu, T. Meng, H. Yin, and J. Zhou. 2013. Polyunsaturated fatty acids promote the expansion of myeloid-derived suppressor cells by activating the JAK/STAT3 pathway. Eur. J. Immunol. 43: 2943-2955.
25. Terme, M., E. Ullrich, L. Aymeric, K. Meinhardt, M. Desbois, N. Delahaye, S. Viaud, B. Ryffel, H. Yagita, G. Kaplanski, et al. 2011. IL-18 induces PD-1-dependent immunosuppression in cancer. Cancer Res. 71: 5393-5399.
26. Johnston, E. M., and J. Crawford. 1998. Hematopoietic growth factors in the reduction of chemotherapeutic toxicity. Semin. Oncol. 25: 552-561.
27. Nefedova, Y., M. Huang, S. Kusmartsev, R. Bhattacharya, P. Cheng, R. Salup, R. Jove, and D. Gabrilovich. 2004. Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J. Immunol. 172: 464-474.
28. Abrams, S. I., and J. D. Waight. 2012. Identification of a G-CSF-granulocytic MDSC axis that promotes tumor progression. OncoImmunology 1: 550-551.
29. Waight, J. D., Q. Hu, A. Miller, S. Liu, and S. I. Abrams. 2011. Tumor-derived G-CSF facilitates neoplastic growth through a granulocytic myeloid-derived suppressor cell-dependent mechanism. PLoS ONE 6: e27690.
30. Nagaraj, S., and D. I. Gabrilovich. 2008. Tumor escape mechanism governed by myeloid-derived suppressor cells. Cancer Res. 68: 2561-2563.
31. Haile, L. A., T. F. Greten, and F. Korangy. 2012. Immune suppression: the hallmark of myeloid derived suppressor cells. Immunol. Invest. 41: 581-594.
32. Youn, J.-I., and D. I. Gabrilovich. 2010. The biology of myeloid-derived suppressor cells: the blessing and the curse of morphological and functional heterogeneity. Eur. J. Immunol. 40: 2969-2975.
33. Dolcetti, L., E. Peranzoni, S. Ugel, I. Marigo, A. Fernandez Gomez, C. Mesa, M. Geilich, G. Winkels, E. Traggiai, A. Casati, et al. 2010. Hierarchy of immunosuppressive strength among myeloid-derived suppressor cell subsets is determined by GM-CSF. Eur. J. Immunol. 40: 22-35.
34. Tse, B. W., P. J. Russell, M. Lochner, I. Förster, and C. A. Power. 2011. IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanisms. PLoS ONE 6: e24241.
35. Cao, R., J. Farnebo, M. Kurimoto, and Y. Cao. 1999. Interleukin-18 acts as an angiogenesis and tumor suppressor. FASEB J. 13: 2195-2202.
36. Ye, Z. B., T. Ma, H. Li, X. L. Jin, and H. M. Xu. 2007. Expression and significance of intratumoral interleukin-12 and interleukin-18 in human gastric carcinoma. World J. Gastroenterol. 13: 1747-1751.
37. Merendino, R. A., S. Gangemi, A. Ruello, A. Bene, E. Losi, G. Lonbardo, and F. Purello-Dambrosio. 2001. Serum levels of interleukin-18 and sICAM-1 in patients affected by breast cancer: preliminary considerations. Int. J. Biol. Markers 16: 126-129.
38. Vidal-Vanaclocha, F., L. Mendoza, N. Telleria, C. Salado, M. Valcárcel, N. Gallot, T. Carrascal, E. Egilegor, J. Beaskoetxea, and C. A. Dinarello. 2006. Clinical and experimental approaches to the pathophysiology of interleukin-18 in cancer progression. Cancer Metastasis Rev. 25: 417-434.
39. Dranoff, G. 2004. Cytokines in cancer pathogenesis and cancer therapy. Nat. Rev. Cancer 4: 11-22.
40. Berman, R. M., T. Suzuki, H. Tahara, P. D. Robbins, S. K. Narula, and M. T. Lotze. 1996. Systemic administration of cellular IL-10 induces an effective, specific, and long-lived immune response against established tumors in mice. J. Immunol. 157: 231-238.
41. Dinarello, C. A. 1999. Interleukin-18. Methods 19: 121-132.
42. Coughlin, C. M., K. E. Salhany, M. Wysocka, E. Aruga, H. Kurzawa, A. E. Chang, C. A. Hunter, J. C. Fox, G. Trinchieri, and W. M. Lee. 1998. Interleukin-12 and interleukin-18 synergistically induce murine tumor regression which involves inhibition of angiogenesis. J. Clin. Invest. 101: 1441-1452.
43. Son, Y. I., R. M. Dallal, R. B. Mailliard, S. Egawa, Z. L. Jonak, and M. T. Lotze. 2001. Interleukin-18 (IL-18) synergizes with IL-2 to enhance cytotoxicity, interferon-gamma production, and expansion of natural killer cells. Cancer Res. 61: 884-888.